Journal
CELL RESEARCH
Volume 25, Issue 11, Pages 1187-1188Publisher
INST BIOCHEMISTRY & CELL BIOLOGY
DOI: 10.1038/cr.2015.127
Keywords
-
Categories
Funding
- Howard Hughes Medical Institute Funding Source: Medline
Ask authors/readers for more resources
BET inhibition has emerged as a promising epigenetic therapy for malignancies in the last five years, but little consensus has developed regarding what may mediate the axis between sensitivity and resistance. Two recent papers published in Nature attempt to address this question in acute myeloid leukemia (AML) and independently identify the Wnt signaling pathway as a driver and biomarker of therapeutic resistance.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
